Current Members

PPTA members produce approximately 80% of the plasma protein therapies used in the United States today and more than 60% worldwide.

Global Members

Bio Products Laboratory
CSL Behring
Grifols
Kedrion SpA
Takeda

European Members

Bio Products Laboratory
CSL Behring GmbH
Grifols International SA
Kedrion SpA
Prothya Biosolutions Netherlands B.V.
Takeda

U.S. Members

ADMA Biologics, Inc.
Bio Products Laboratory
CSL Behring
Grifols
Kedrion SpA
Takeda

Plasma Members

ABO Plasma
Access Plasma LLC
B Positive Plasma LLC
BioLife Plasma Services LP/(Takeda)
Biomat USA LLC (Grifols)
BioTek America, LLC (dba Freedom Plasma)
BPL Plasma Inc.
Canadian Plasma Resources
CSL Plasma
Europlasma GmbH
Grifols Egypt for Plasma Derivatives, S.A.E.
Hemarus LLC
Immunotek Bio Centers LLC
Kamada Plasma, LLC
KEDPlasma LLC
Kedrion SpA
Octapharma Plasma
PlasmaVita
Prometic Plasma Resources
Scantibodies Biologics
Southern Blood Services
UNICAplasma s.r.o

Associate Members

Abbott Laboratories Diagnostic Division
ABO Pharmaceuticals
AOSS Medical Supply
Blood Centers of America (BCA)
Evolve Biologics Inc.
Fresenius Kabi
Haemonetics Corporation
Headspring Healthcare, Inc.
HemaSource
Kamada Ltd.
Lychem International Ltd.
Marketing Research Bureau Inc.
National Genetics Institute
Onbe
Paysign, Inc.
PreviPharma Consulting GmbH
QualTex Laboratories
Roche Diagnostics
Secure Transfusion Services
Terumo BCT
Vizient Inc.

Membership

PPTA News

PPTA Statement on the draft EU Substances of Human Origin Regulation +

PPTA welcomes positive developments but regrets missed opportunities to support plasma donors and patients who rely on plasma-derived medicinal products (PDMPs)

Brussels, Belgium (July 14, 2022). While the text of the draft regulation on Substances of Human Origin (SoHo) addresses a number of PPTA’s concerns, it has missed the opportunity to help Member States increase plasma collection to improve the reliable availability of life-saving, plasma-derived therapies to patients with a wide range of rare and complex, chronic diseases. As much as 38% of the plasma used to produce medicines for the EU’s 300,000 rare disease patients who rely on PDMPs comes from the U.S., a reliance highlighted during the pandemic, when critical plasma donations declined significantly.
Read More
Monkeypox Virus and Plasma Protein Therapies +

PPTA considers that the current MPXV outbreak is not a concern for the safety margins of plasma protein therapies manufactured by PPTA member companies. This assessment is also shared by other concerned parties (AABB, WHO).

Since May 2022, Monkeypox virus (MPXV) infections have been reported in non-endemic countries across Europe and North America (WHO, CDC, ECDC). People who use plasma protein therapies are understandably concerned about whether their therapies remain safe, with respect to MPXV. To address this issue, PPTA has summarized currently available facts.
Read More
Announcing PPTA’s New Global Chair +

It is with great pleasure that the Plasma Protein Therapeutics Association (PPTA) announces the election of Giles Platford from Takeda to the Chair of the PPTA Global Board.
Read More
Public Review until August 31: Proposed Confirmation of IQPP Standard for Recording Donor Adverse Events +
The following proposed actions are hereby opened for public review:
- Confirmation (continued implementation) of Version 2.0 of the IQPP Standard for Recording Donor Adverse Events
Resulting from a scheduled review by the PPTA IQPP Standards Committee and discussion by the PPTA Global Plasma Board of Directors, it was agreed that this document should be “confirmed.” In other words, it was agreed that the document should continue to be implemented as part of the IQPP Standards Program, without change. Members of the public are invited to comment on this proposed action. The text of the standards themselves is not being considered for revision at this time.
Read More

1
2
3

› ‹

The Source, the international magazine of the plasma protein therapeutics industry, is published three times a year.

Learn more about the need for plasma donors, plasma donation, and how you can save and improve lives.
Find a Donation Center.

The need for plasma and plasma donors is more urgent than ever before. Visit givingplasma.org to learn more and to find a donation center near you.

"How Is Your Day?" is an initiative to raise awareness of the unique nature of plasma protein therapies and the value they provide to patients. It aims to inform and educate decision makers and the general public worldwide.

Get involved and follow "How Is Your Day?" on social media @HIYDglobal

Media and Information

Advocacy

Copyright © 2022 PPTA. All rights reserved. (202) 789-3100

Terms of Use | Privacy Statement | Sitemap